cgen.com (CGEN): Rasio utang jangka dawa marang modal

Compugen Ltd. (CGEN) business growth is driven by successful tumor antibody trials and partner payments, while the standalone long-term debt-to-equity ratio stands at 0.03. The tracked price action on the chart complements data regarding the application of AI for discovering new immunotherapy targets. Compugen Ltd. (CGEN) relies on licensing agreements with pharmaceutical leaders, favoring strategic alliances over direct acquisitions.

Conservative capital requires transparency in the leverage structure to assess business resilience to external shocks. This ratio correlates liabilities with a maturity of over one year against equity, determining the company's ability to finance growth without the risk of an immediate loss of liquidity. For Compugen Ltd. (CGEN) and its R&D centers in the US, this is critical, as reflected by the long-term debt-to-equity ratio.